DFTX · Definium Therapeutics
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $38.95
Note written ·
Price against the kill line
17.6% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $38.95, on record since 11 November 2026. The shares are down 29.1% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $38.95, well above the 50-day moving average, which would show the shares leading the S&P 500; or Definium disclosing that the FDA agreed the current Phase 3 data support a first-half 2027 NDA filing.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 9 November 2026
- Net cash, cash less debt ($M)
- 1,010
All filed numbers
What Definium Therapeutics reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −338 | −51.0 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +59.9 |
| Operating cash flow ($M) | −191 |
| Capital spending ($M) | Not reported |
| Free cash flow ($M) | Not available |
| Cash and short-term investments ($M) | 1,047 |
| Debt ($M) non-current long-term debt | 36.7 |
| Net cash, cash less debt ($M) | 1,010 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 968 |
| Market value ($M) | 4,392 |
| Enterprise value, market value plus net debt ($M) | 3,382 |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 4.5 |
| Free-cash-flow yield (%) | Not available |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 7.3% of shares outstanding sold short, 4.9 days of average trading to cover, −11.5% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $3.0M |
| 12 monthsfrom | $0 | $7.0M |
The thesis
Definium Therapeutics shares are more likely to lag the S&P 500 over the next three months. The 9 November 2026 third-quarter report kept the DT120 filing plan on track, but the shares closed lower the next session. They remain below their 50-day moving average. The fourth-quarter 2026 pre-filing meeting with the US Food and Drug Administration (FDA) settles the call. The company has not given it a date.
The report gave buyers little that was new. Definium said it is "on track" to file a new drug application (NDA) for DT120 in the first half of 2027. It held about $1.05 billion in cash, cash equivalents and investments at 30 September 2026, which it says funds operations into 2030. The shares closed at $35.39 on 9 November 2026, before the after-market release. They closed at $34.64 on 10 November 2026 and $34.47 on 11 November 2026. Q3 release
The clinical case is already settled. Voyage and Panorama both met their primary endpoints in generalized anxiety disorder (GAD), and Emerge did the same in major depressive disorder (MDD). The remaining questions are regulatory and commercial, and none has a dated answer. The rating is Low because the stock has no dated event that could move it before the FDA meeting outcome is disclosed.
Bullish and bearish views on Definium Therapeutics, Inc.
The bull case on Definium Therapeutics, Inc. (DFTX), in brief: three positive Phase 3 readouts. The bear case: the report did not lift the shares.
Bull case
- Three positive Phase 3 readouts. Panorama showed a 5.1-point placebo-adjusted improvement on the Hamilton Anxiety Rating Scale (HAM-A) at Week 12 for the 100-microgram dose (p<0.0001), per the company's 14 September 2026 Form 8-K. Voyage showed 5.4 points, and the 9 November 2026 release says Emerge met its primary endpoint and all key secondary efficacy endpoints in MDD.
- Second Breakthrough Therapy designation. The FDA granted DT120 Breakthrough Therapy designation in MDD during the third quarter, per the 9 November 2026 release. DT120 now holds the designation in both GAD and MDD, and the designation brings closer FDA engagement during review.
- Runway into 2030. Cash, equivalents and investments were about $1.05 billion at 30 September 2026, up from $411.6 million at 31 December 2025, per the third-quarter release. The company says this funds operations into 2030, past the planned first-half 2027 filing.
- Loss narrowed and beat estimates. The third-quarter net loss was $51.0 million, or $(0.46) per diluted share, against $67.3 million a year earlier, per the 9 November 2026 release. The consensus estimate was $(0.56), per news reports on 9 November 2026. The release attributes much of the smaller loss to a warrant fair-value gain and higher interest income.
- Analysts held or raised targets after the report. RBC Capital raised its target to $70 from $66 and kept an Outperform rating on 10 November 2026. Oppenheimer kept a Buy rating and a $75 target on 11 November 2026.
Bear case
- The report did not lift the shares. The 10 November 2026 close of $34.64 was below the 9 November 2026 pre-report close of $35.39. The shares are 30.6% below the 52-week intraday high of $49.70 set on 7 August 2026.
- The FDA meeting has no date. The 14 September 2026 Form 8-K placed the pre-filing meeting in the fourth quarter of 2026. The third-quarter release reaffirms the first-half 2027 filing but gives no meeting date and does not say which indication the first filing will cover.
- Spending is climbing ahead of any revenue. Third-quarter research and development expense was $46.1 million against $31.0 million a year earlier. General and administrative expense was $26.1 million against $14.7 million, including $3.4 million for commercial preparation, per the 9 November 2026 release. Definium has no approved product.
- Executives sold into the September price range. SEC Form 4 filings show the chief executive sold 31,550 shares and the chief legal officer 14,051 shares at $36.57 on 25 September 2026. Three other officers also sold that day. All five sales were under Rule 10b5-1 trading plans.
- Delivery and scheduling add friction. Panorama participants averaged 6.2 hours to meet end-of-session criteria, per the 14 September 2026 report. The 9 November 2026 release lists rescheduling by the Drug Enforcement Administration (DEA) and the states as a requirement before any Schedule I product candidate can be sold in the US.
Price setup
The shares closed at $34.47 on 11 November 2026, per adjusted daily closes. That close sits below the 50-day moving average of $36.31 and above the 200-day moving average of $30.27, both as of 11 November 2026. The three-month change is −21.5%, measured from the $43.90 close on 13 August 2026.
The recent low close was $30.36 on 5 November 2026. The shares recovered to $35.39 on 9 November 2026 and then slipped after the report. Reclaiming the 50-day average would be the first sign the shares have stopped trending lower since the August highs. The 52-week closing low of $10.68 on 21 November 2025 came before the Phase 3 readouts.
The June 2026 offering priced at $34 per share, per the company. The 11 November 2026 close is just above that level.
Catalysts ahead
- ~31 December 2026 (est.): Pre-new-drug-application meeting with the FDA for DT120, guided to the fourth quarter of 2026 with no disclosed day. The outcome decides whether the first-half 2027 filing holds, which indication it covers, or whether the FDA asks for more data.
- ~26 February 2027 (est.): Fourth-quarter and full-year 2026 results. Shows the year-end cash balance against the runway into 2030 and may confirm the FDA meeting outcome and the filing date.
- ~30 June 2027 (est.): Anticipated DT120 new drug application, guided to the first half of 2027. A filing starts the FDA review clock and sets up a possible approval decision date.
- ~30 June 2027 (est.): First Commercial Day, planned for the first half of 2027. Gives the first detail on launch costs, treatment-site capacity and reimbursement for multi-hour supervised dosing.
What would change the view
A daily close above $38.95, well above the 50-day moving average, which would show the shares leading the S&P 500; or Definium disclosing that the FDA agreed the current Phase 3 data support a first-half 2027 NDA filing.
What it trades with
Definium trades with other psychedelic-medicine developers and with small and mid-sized clinical-stage biotech shares. That group responds to financing conditions, FDA sentiment and news on DEA scheduling. Three months of post-data trading is too short a sample to measure a stable link to any peer group or index. Definium-specific events, chiefly the FDA meeting outcome and the NDA filing, are expected to move the shares more than sector moves.
The evidence, claim by claim (8)
- Cash, cash equivalents and investments were about $1.05 billion at 30 September 2026; the company says this funds operations into 2030. Definium Q3 2026 results release, 9 November 2026 · as of
- Q3 2026 R&D expense $46.1 million vs $31.0 million in Q3 2025; G&A $26.1 million vs $14.7 million, including $3.4 million for commercial preparation. Definium Q3 2026 results release, 9 November 2026 · as of
- Q3 2026 net loss $51.0 million, or $(0.46) per diluted share, vs $67.3 million in Q3 2025. Definium Q3 2026 results release, 9 November 2026 · as of
- The FDA granted DT120 Breakthrough Therapy designation in major depressive disorder during Q3 2026; DT120 holds the designation in GAD and MDD. Definium Q3 2026 results release, 9 November 2026 · as of
- Definium says it is on track to file a DT120 new drug application in the first half of 2027. Definium Q3 2026 results release, 9 November 2026 · as of
- Panorama met its primary endpoint with a 5.1-point placebo-adjusted Week 12 HAM-A improvement for DT120 100 micrograms, p<0.0001. Definium Form 8-K, Exhibit 99.1, 14 September 2026 · as of
- RBC Capital raised its Definium price target to $70 from $66 and kept an Outperform rating. RBC Capital note reported 10 November 2026 · as of
- CEO Robert Barrow sold 31,550 shares at $36.57 on 25 September 2026 under a Rule 10b5-1 plan. SEC Form 4 filed 29 September 2026 · as of
Sources
- ir.definiumtx.com ·
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder · secure.businesswire.com ·
- Definium Q3: $1.05 Billion Cash Funds DT120 ODT NDA Filing on 58% Higher Operating Expenses · panabee.com ·
- Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights · secure.businesswire.com ·
Related · shared themes
ZVRA
Zevra Therapeutics
Zevra Therapeutics is modestly more likely to beat the S&P 500 over three months: MIPLYFFA sold $34.0 million in the third quarter of 2026…
ABCL
AbCellera Biologics
AbCellera's shares look more likely to lag the S&P 500 over three months, because the case rests on unproven repeat dosing of ABCL635, its…
IBRX
ImmunityBio
ImmunityBio's third-quarter Anktiva revenue of $48.7 million fell below the second quarter's $50.7 million, and the shares are more likely…
KOD
Kodiak Sciences
Kodiak Sciences' shares look more likely to lag the S&P 500 after a 161.8% three-month run that prices in the DAYBREAK win while share…